Latest News - Glaucoma

Wednesday, March 22, 2017 | Glaucoma, Medical Studies

Body-tilt Test Helps Predict Optic Nerve Tissue Loss in Glaucoma

Changes in pattern electroretinogram (PERG) and other measures associated with head-down-body-tilt (HDT) position predict future loss of optic nerve tissue in individuals at risk for glaucoma, accordi…

Read the full story

Tuesday, March 21, 2017 | Glaucoma, Bausch+Lomb, Nicox

Bausch + Lomb and Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod

Bausch + Lomb and Nicox announced that the FDA has set a deadline of August 24, 2017 for its decision on the new drug application for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene b…

Read the full story

Thursday, March 16, 2017 | Glaucoma, Glaukos Corporation, MIGS

Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Microinvasive Glaucoma Surgery

Glaukos announced that the Current Procedural Terminology (CPT) Editorial Panel of the American Medical Association has granted 5-year extensions to three Category III CPT codes that describe insertio…

Read the full story

Monday, March 06, 2017 | Glaucoma, Medical Studies

24-Hour Monitoring Gives Long View of Glaucoma

Tracking intraocular pressure for 24-hours using a contact-lens sensor can help physicians predict the speed of vision loss over the subsequent 5 years in patients who have been treated for glaucoma, …

Read the full story

Monday, March 06, 2017 | Glaucoma, Medical Studies

Corneal Patch Graft More Likely to Erode Than Scleral Graft

In patients who have undergone implantation of a glaucoma drainage device, corneal patch grafts are much more likely to erode than scleral patch grafts, leading to more frequent revision for the preve…

Read the full story

Monday, February 27, 2017 | Glaucoma, Bausch+Lomb, Nicox

Bausch + Lomb And Nicox Resubmit FDA New Drug Application For Glaucoma Candidate Latanoprostene Bunod

Bausch + Lomb and Nicox announced the resubmission of a new drug application (NDA) to the FDA seeking approval for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene bunod is an IOP-lowe…

Read the full story

Friday, February 24, 2017 | Conferences, Glaucoma, Inotek Pharmaceuticals

Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual Meeting

Inotek Pharmaceuticals announced three poster presentations at the American Glaucoma Society 2017 Annual Meeting to be held March 2-5 in Coronado, California. The presentation details are as follows: …

Read the full story

Friday, February 24, 2017 | Glaucoma, Medical Studies

Surgical Techniques Showcased at Glaucoma Meeting

A new analysis of 5-year pooled data from two studies, along with highly anticipated reports on new surgical techniques, will be in the spotlight at the upcoming American Glaucoma Society (AGS) 2017 A…

Read the full story

Thursday, February 23, 2017 | Glaucoma, Partnerships, Santen

Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments

Santen and twoXAR, an artificial intelligence-driven biopharmaceutical company, announced that the two companies have entered into a strategic research collaboration focused on the identification of n…

Read the full story

Tuesday, February 14, 2017 | Glaucoma, Allergan, MIGS

Allergan Announces First Commercial Use of XEN Glaucoma Treatment System in the US

Allergan announced that its XEN Glaucoma Treatment System is now being used by US surgeons to treat refractory glaucoma. The XEN Glaucoma Treatment System, consisting of the XEN45 Gel Stent and the XE…

Read the full story

Monday, January 09, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland

Aerie Pharmaceuticals announced that it has entered into a lease agreement with the Industrial Development Agency (IDA) of Ireland for a new manufacturing plant in Athlone, Ireland. This will be Aerie…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies

Three-year Study Shows Significant Advantages of CLASS (CO2 Laser Assisted Sclerectomy Surgery) for Patients with Glaucoma

IOPtima announced the publication of 3-year follow up data from a multicenter study of patients undergoing CLASS (CO2 Laser Assisted Sclerectomy Surgery) with IOPtima’s IOPtiMate CO2 laser syste…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies, Glaukos Corporation

Study Published in Journal of Glaucoma Evaluates a Single Glaukos iStent Trabecular Micro-Bypass Stent as a Standalone Procedure

Glaukos Corporation announced that a study published recently in the Journal of Glaucoma showed that a single iStent Trabecular Micro-Bypass Stent significantly reduced IOP when implanted as a standal…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies

Antihypertensive Medications May Have Protective Effect Against Developing Glaucoma

Antihypertensive medications may have a preventive effect on developing glaucoma in people 40 years old or older, according to results of a study of the Danish population[1]. "Cardiologists shoul…

Read the full story

Thursday, December 01, 2016 | Glaucoma

Zika and Glaucoma Linked for First Time in New Study

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus dur…

Read the full story
Load More